PreprintCited by 533Pancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsCholangiocarcinoma and Gallbladder Cancer Studies

The DOI matches its Crossref record; 394 of the 394 references it cites were found in a registry or an index.

Genetics and biology of pancreatic ductal adenocarcinoma

Open access

Ying, Haoqiang, Dey, Prasenjit, Yao, Wantong, Kimmelman, Alec C., Draetta, Giulio F., Maitra, Anirban, DePinho, Ronald A.·2016·Genes & Development

DOI 10.1101/gad.275776.115

Open this paper in CoChat — free account

Abstract

With 5-year survival rates remaining constant at 6% and rising incidences associated with an epidemic in obesity and metabolic syndrome, pancreatic ductal adenocarcinoma (PDAC) is on track to become the second most common cause of cancer-related deaths by 2030. The high mortality rate of PDAC stems primarily from the lack of early diagnosis and ineffective treatment for advanced tumors. During the past decade, the comprehensive atlas of genomic alterations, the prominence of specific pathways, the preclinical validation of such emerging targets, sophisticated preclinical model systems, and the molecular classification of PDAC into specific disease subtypes have all converged to illuminate drug discovery programs with clearer clinical path hypotheses. A deeper understanding of cancer cell biology, particularly altered cancer cell metabolism and impaired DNA repair processes, is providing novel therapeutic strategies that show strong preclinical activity. Elucidation of tumor biology principles, most notably a deeper understanding of the complexity of immune regulation in the tumor microenvironment, has provided an exciting framework to reawaken the immune system to attack PDAC cancer cells. While the long road of translation lies ahead, the path to meaningful clinical progress has never been clearer to improve PDAC patient survival.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.275776.115

Cites

394 of 394 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783

Show all 392 references

Research works printed but not linked: 1

Kloppel G . 2000. WHO classification of tumours. IARC Press, Lyon, France.

Sorted by citations

Items 301–400 of 533

Crosstalk between miRNAs and signaling pathways involved in pancreatic cancer and pancreatic ductal adenocarcinoma
Lotfi, Z., Najjary, S., Lotfi, F., Amini, M. A., Baghbanzadeh, A., Rashid, D. J., Asl, E. R., Baradaran, B., & Mokhtarzadeh, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174006 · Cited by 14
Harnessing epigenetic inhibitors: A promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment
Maietta, I., González‐Fernández, Á., & Simón‐Vázquez, R. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115638 · Cited by 13
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment
Arnold, F., Vecchio, A. D., Hussain, Z., & Sherman, M. H. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00905-9 · Cited by 15
Metabolic landscape of the healthy pancreas and pancreatic tumor microenvironment
Bonilla, M. E., Radyk, M. D., Perricone, M. D., Elhossiny, A. M., Harold, A. C., Medina-Cabrera, P. I., Kadiyala, P., Shi, J., Frankel, T. L., Carpenter, E. S., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.180114 · Cited by 12
Overexpressing PLOD Family Genes Predict Poor Prognosis in Pancreatic Cancer
Zhang, J., Tian, Y., Mo, S., & Fu, X. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 12
Atypical flat lesions derive from pancreatic acinar cells
von Figura, G., Fahrenkrog-Petersen, L., Hidalgo‐Sastre, A., Hartmann, D., Hüser, N., Schmid, R. M., Hebrok, M., Roy, N., & Esposito, I. (2017) · Pancreatology · doi:10.1016/j.pan.2017.04.014 · Cited by 12
Dietary molecules and experimental evidence of epigenetic influence in cancer chemoprevention: An insight
Ullah, M. F., Usmani, S. A., Shah, A., & Abuduhier, F. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.011 · Cited by 12
Pancreatic Cancer Cells Induce MicroRNA Deregulation in Platelets
Díaz-Blancas, J. Y., Domínguez-Rosado, I., Chan-Núñez, C., Meléndez-Zajgla, J., & Maldonado, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911438 · Cited by 11
Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality
Donahue, T. R., & Dawson, D. W. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.06.009 · Cited by 11
Carboxypeptidase E-∆N Promotes Proliferation and Invasion of Pancreatic Cancer Cells via Upregulation of CXCR2 Gene Expression
Hareendran, S., Yang, X.-Y., Lou, H., Xiao, L., & Loh, Y. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225725 · Cited by 11
Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers
Mottini, C., & Cardone, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145023 · Cited by 11
Pan-Sigma Receptor Modulator RC-106 Induces Terminal Unfolded Protein Response In In Vitro Pancreatic Cancer Model
Cortesi, M., Zamagni, A., Pignatta, S., Zanoni, M., Arienti, C., Rossi, D., Collina, S., & Tesei, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239012 · Cited by 11
Matrix Metalloproteinase 8 Expression in a Tumour Predicts a Favourable Prognosis in Pancreatic Ductal Adenocarcinoma
Kaasinen, M., Hagström, J., Mustonen, H. K., Sorsa, T. A., Sund, M., Haglund, C. H., & Seppänen, H. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063314 · Cited by 10
The Key Role of COA6 in Pancreatic Ductal Adenocarcinoma: Metabolic Reprogramming and Regulation of the Immune Microenvironment
Jiang, L., Jiang, Y., Zhou, X., Wang, L., Zhang, S., Jiang, C., Meng, H., Gu, Y., Fu, Y., Xu, K., et al. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70685 · Cited by 10
Oncogenic signaling pathways in pancreatic ductal adenocarcinoma
Agrawal, R., & Natarajan, K. N. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.006 · Cited by 10
Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer
Wright, C., Gordon, E. R., & Cooper, S. J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11645-0 · Cited by 10
Epigenetic small-molecule screen for inhibition and reversal of acinar ductal metaplasia in mouse pancreatic organoids
Atanasova, K. R., Perkins, C. M., Ratnayake, R., Jiang, J., Chen, Q.-Y., Schmittgen, T. D., & Luesch, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1335246 · Cited by 12
Expression patterns and prognostic values of the cyclin-dependent kinase 1 and cyclin A2 gene cluster in pancreatic adenocarcinoma
Jiang, P., Zhang, M., Gui, L., & Zhang, K. (2020) · Journal of International Medical Research · doi:10.1177/0300060520930113 · Cited by 10
Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions
Suri, R., Zimmerman, J. W., & Burkhart, R. A. (2020) · Annals of Pancreatic Cancer · doi:10.21037/apc-20-29 · Cited by 11
PAF1 Regulates the Stemness of Pancreatic Cancer Stem Cells
Feng, Y., Mouti, M. A., & Pauklin, S. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.201 · Cited by 10
Fragment-based drug discovery of small molecule ligands for the human chemokine CCL28
Zhou, A. L., Jensen, D. R., Peterson, F. C., Thomas, M. A., Schlimgen, R. R., Dwinell, M. B., Smith, B. C., & Volkman, B. F. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.02.004 · Cited by 10
Potential clinical applications of extracellular vesicles in pancreatic cancer: exploring untapped opportunities from biomarkers to novel therapeutic approaches
Sanchez-Manas, J. M., de Gracia, N. P., Perales, S., Martínez-Galán, J., Torres, C., & Real, P. J. (2024) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.68 · Cited by 9
Pancreatic cancer subtyping - the keystone of precision treatment
Fan, Z., Xiao, Y., Du, Y., Zhang, Y., & Zhou, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1563725 · Cited by 9
Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy
Galanopoulos, M., Doukatas, A., Gkeros, F., Viazis, N., & Liatsos, C. N. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i24.3568 · Cited by 9
Exosomal miRNAs in the microenvironment of pancreatic cancer
Zou, X., Huang, Z., Guan, C., Shi, W., Gao, J., Wang, J., Cui, Y., Wang, M., Xu, Y., & Zhong, X. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117360 · Cited by 10
Cytokine CCL9 Mediates Oncogenic KRAS-Induced Pancreatic Acinar-to-Ductal Metaplasia by Promoting Reactive Oxygen Species and Metalloproteinases
Liou, G., Byrd, C. J., Störz, P., & Messex, J. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094726 · Cited by 8
Establishment of a non‑coding RNAomics screening platform for the regulation of KRAS in pancreatic cancer by RNA sequencing
Zhang, L., Yu, S., Wang, C., Jia, C., Lu, Z., & Chen, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4560 · Cited by 9
RETRACTED: Knockdown EIF3C Suppresses Cell Proliferation and Increases Apoptosis in Pancreatic Cancer Cell
Jiao, H., Zeng, L., Yang, S., Zhang, J., & Lou, W. (2020) · Dose-Response · doi:10.1177/1559325820950061 · Cited by 9
Retracted
Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma
Pook, H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13194834 · Cited by 10
β-Hydroxyisovaleryl-Shikonin Exerts an Antitumor Effect on Pancreatic Cancer Through the PI3K/AKT Signaling Pathway
Zeng, Y., Zhang, H., Zhu, M., Pu, Q., Li, J., & Hu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.904258 · Cited by 9
Clonal dominance defines metastatic dissemination in pancreatic cancer
Ho, I.-L., Li, C.-Y., Wang, F., Zhao, L., Liu, J., Yen, E.-Y., Dyke, C. A., Shah, R., Liu, Z., Çetin, A. O., et al. (2024) · Science Advances · doi:10.1126/sciadv.add9342 · Cited by 9
Self-citation
Fibroblasts form a hospitable metastatic niche in the liver
Erez, N. (2016) · Nature Cell Biology · doi:10.1038/ncb3352 · Cited by 9
Effects of Immunonutrition on Comprehensive Complication Index in Patients Undergoing Pancreatoduodenectomy
Tumas, J., Jasiūnas, E., Strupas, K., & Šileikis, A. (2020) · Medicina · doi:10.3390/medicina56020052 · Cited by 9
Clinical significance of pancreatic ductal metaplasia
Jiang, T., Fang, W., & Xie, K. (2022) · The Journal of Pathology · doi:10.1002/path.5883 · Cited by 8
PKCι regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cells
Zhang, H., Zhu, Y., Wang, J., Weng, S., Zuo, F., Li, C., & Zhu, T. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110115 · Cited by 8
Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand–Addicted Pancreatic Cancer
Aguilera, K. Y., Le, T. M., Riahi, R., Lay, A. R., Hinz, S., Saadat, E. A., Vashisht, A. A., Wohlschlegel, J. A., Donahue, T. R., Radu, C. G., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0623 · Cited by 8
Differential extracellular vesicle concentration and their biomarker expression of integrin αv/β5, EpCAM, and glypican-1 in pancreatic cancer models
Jacobson, R. I., Ha, S., Tani, S., Ghosh, S., Jarajapu, Y. P. R., Brand, R. E., Kim, J., & Choi, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-65209-8 · Cited by 7
DNA Origami‐Cyanine Nanocomplex for Precision Imaging of KRAS‐Mutant Pancreatic Cancer Cells
Moon, H., Du, Y., Choi, S. R., Seo, S., Cheng, C., Elzey, B. D., Choi, J. H., & Han, B. (2025) · Advanced Science · doi:10.1002/advs.202410278 · Cited by 7
Improving Access to Hereditary Testing in Pancreatic Ductal Carcinoma
Cremin, C., Bedard, A. C., Hong, Q., Mung, S. W., Nuk, J., Wong, A., Akbar, H., Cheung, E., Renouf, D. J., Schaeffer, D., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00167 · Cited by 8
The application of pancreatic cancer organoids for novel drug discovery
Melzer, M. K., Resheq, Y. J., Navaee, F., & Kleger, A. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2194627 · Cited by 7
AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor
Ingle, K., LaComb, J. F., Graves, L. M., Baines, A. T., & Bialkowska, A. B. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294065 · Cited by 7
Circular RNA hsa_circ_0001846 facilitates the malignant behaviors of pancreatic cancer by sponging miR-204-3p and upregulating KRAS expression
Ma, X., Zhang, H., Wang, L., Cheng, M., Jia, Y., Feng, D., Lei, Y., Li, X., Ba, L., Song, N., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01733-2 · Cited by 7
Forskolin sensitizes pancreatic cancer cells to gemcitabine via Stat3 and Erk1/2 inhibition
Illiano, M., Sapio, L., Caiafa, I., Chiosi, E., Spina, A., Naviglio, S., & work., †. T. T. A. E. C. T. T. (2017) · AIMS molecular science · doi:10.3934/molsci.2017.2.224 · Cited by 7
Ubiquitin‐independent, Proteasome‐mediated targeted degradation of KRAS in pancreatic adenocarcinoma cells using an engineered ornithine decarboxylase/antizyme system
Ma, Y., Xu, J., Huang, P., Bai, X., & Hanqing, G. (2018) · IUBMB Life · doi:10.1002/iub.1945 · Cited by 7
Identification of prognosis-related genes and construction of multi-regulatory networks in pancreatic cancer microenvironment by bioinformatics analysis
Li, T., Liu, Q., Zhang, R., Liao, Q., & Zhao, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01426-1 · Cited by 7
microRNAs: Novel regulators of the TGF-β pathway in pancreatic ductal adenocarcinoma
Ottaviani, S., & Castellano, L. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1499066 · Cited by 7
Unveiling the Molecular Landscape of Pancreatic Ductal Adenocarcinoma: Insights into the Role of the COMPASS-like Complex
Jamali, M., Barar, E., & Shi, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105069 · Cited by 6
Unraveling the glyco-immunity nexus in pancreatic cancer
Rajesh, C., Cummings, R. D., & Radhakrishnan, P. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02417-4 · Cited by 6
PKCι induces differential phosphorylation of STAT3 to modify STAT3-related signaling pathways in pancreatic cancer cells
Wang, J., Weng, S., Zhu, Y., Chen, H., Pan, J., Qiu, S., Liu, Y., Wei, D., & Zhu, T. (2023) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-023-00780-9 · Cited by 6
MicroRNA 211-5p inhibits cancer cell proliferation and migration in pancreatic cancer by targeting BMP2
Li, D., Luo, C. H., Deng, J., Xu, Y., Fu, S., Liu, K., & Wu, J. (2023) · Aging · doi:10.18632/aging.205320 · Cited by 6
N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer
Wen, Y.-R., Lin, X.-W., Zhou, Y., Xu, L., Zhang, J., Chen, C., & He, J. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i3.659 · Cited by 6
Epigenetic regulation of the tumor microenvironment: A leading force driving pancreatic cancer
Vera, R. E., Lamberti, M. J., González, A. L., & Fernández-Zapico, M. E. (2024) · Pancreatology · doi:10.1016/j.pan.2024.07.005 · Cited by 6
High expression of diffuse panbronchiolitis critical region 1 gene promotes cell proliferation, migration and invasion in pancreatic ductal adenocarcinoma
Yan, J., Chen, G., Zhao, X., Chen, F., Wang, T., & Miao, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.031 · Cited by 6
Molecular signaling in pancreatic ductal metaplasia: emerging biomarkers for detection and intervention of early pancreatic cancer
Li, X., He, J., & Xie, K. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00664-x · Cited by 6
High-throughput functional screen identifies YWHAZ as a key regulator of pancreatic cancer metastasis
Cao, F., Jiang, Y., Chang, L., Du, H., Chang, D., Pan, C., Huang, X., Yu, D., Zhang, M., Fan, Y., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05951-5 · Cited by 6
Novel Methodology for the Design of Personalized Cancer Vaccine Targeting Neoantigens: Application to Pancreatic Ductal Adenocarcinoma
Savsani, K., & Dakshanamurthy, S. (2024) · Diseases · doi:10.3390/diseases12070149 · Cited by 6
Hyaluronic Acid Fuels Pancreatic Cancer GrowthPreprint
Kim, P. K., Halbrook, C. J., Kerk, S. A., Wisner, S., Kremer, D. M., Sajjakulnukit, P., Hou, S. W., Thurston, G., Anand, A., Liang, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.14.293803 · Cited by 6
Self-citation
Personalized nutrition after discharge for pancreatic surgery: A study protocol
Pizzocaro, E., Vella, R., Frigerio, I., Giardino, A., Regi, P., Scopelliti, F., Bannone, E., Girelli, R., Bignotto, L., Mas, F. D., et al. (2024) · Nutrition and Health · doi:10.1177/02601060241290281 · Cited by 5
Magnetic targeting enhances nanostructured covalent organic framework-doxorubicin cellular uptake in triple-negative breast cancer: A model for receptor-deficient cancers
Torshizi, S. R. N., Seyf, J. Y., Najafi, R., Ventura, D., Mahdavinezhad, A., Afshar, S., Jalilian, F. A., Shojaeian, A., Amini, R., & Pecic, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147169 · Cited by 5
Dual Inhibition of KRAS G12D and PI3K/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer
Ghanwatkar, Y., Mahto, S., Chittipolu, A., Ramanathan, R., Shrestha, P., & Mahato, R. I. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.12.049 · Cited by 7
Transcriptional and epigenetic regulation of autophagy: mechanisms, disease relevance and therapeutic opportunities
Seo, J., Park, S., Lee, D. C., Yoo, W., Yang, Y. R., Seo, H. W., Park, J. L., Joo, J., Park, K. C., & Byun, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02688-3 · Cited by 5
Species-Deconvolved Proteomics for In Situ Investigation of Tumor-Stroma Interactions after Treatment of Pancreatic Cancer Patient-Derived Xenografts with Combined Gemcitabine and Paclitaxel
Wang, X., Niu, J., Qian, S., Shen, S., Straubinger, R. M., & Qu, J. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00164 · Cited by 5
Systematic analysis of proteome turnover in an organoid model of pancreatic cancer by dSILO
Ross, A. B., Gorhe, D., Kim, J. K., Hodapp, S. J., DeVine, L., Chan, K. M., Chio, I. I. C., Jovanović, M., & Pereira, M. A. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100760 · Cited by 5
A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma
Yang, H., Zhang, W., Ding, J., Hu, J., Sun, Y. E., Peng, W., Chu, Y., Xie, L., Mei, Z., Shao, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.970588 · Cited by 5
Machine Learning-Based Model Helps to Decide which Patients May Benefit from Pancreatoduodenectomy
Vigia, E., Ramalhete, L., Filipe, E., Bicho, L., Nobre, A. M., Mira, P., Macedo, M., Aguiar, C., Corado, S. C., Chumbinho, B., et al. (2023) · Onco · doi:10.3390/onco3030013 · Cited by 5
Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients
Waldenmaier, M., Schulte, L.-A., Schönfelder, J., Fürstberger, A., Kraus, J. M., Daiß, N., Seibold, T., Morawe, M., Ettrich, T. J., Kestler, H. A., et al. (2022) · Cancers · doi:10.3390/cancers14041074 · Cited by 5
Oncogenic KRAS, Mucin 4, and Activin A‐Mediated Fibroblast Activation Cooperate for PanIN Initiation
Hu, C., Huang, C., Hsu, M., Chien, H., Wu, P., Chen, Y., Jeng, Y., Tang, S., Chung, M., Shen, C., et al. (2023) · Advanced Science · doi:10.1002/advs.202301240 · Cited by 5
Impact of genetic variants of ABCB1, APOB, CAV1, and NAMPT on susceptibility to pancreatic ductal adenocarcinoma in Chinese patients
Li, B., Zhang, C., Wang, J., Zhang, M., Liu, C., & Chen, Z. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1226 · Cited by 6
Necroptosis DAMPens anti-tumor immunity
Shibata, K., Omahdi, Z., & Yamasaki, S. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.33 · Cited by 5
Safety and efficacy of KRAS antisense oligonucleotides and RIG-I agonists delivered by extracellular vesicles for pancreatic cancer peritoneal metastasis treatment
Nguyen, T. T. T., Dang, X. T. T., Phung, C. D., Tran, L. T. N., Do, N. T. P., Yeo, E. Y. M., Tran, N. M., Yeo, B. Z. J., Lixuan, C. P., Nguyen, N. T. H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114239 · Cited by 4
Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma
Kluz, N., Kraj, L., Chmiel, P., Przybyłkowski, A. M., Wyrwicz, L. S., Stec, R., & Szymański, Ł. (2024) · Cancers · doi:10.3390/cancers16233945 · Cited by 5
Cystic Fluid Total Proteins, Low-Density Lipoprotein Cholesterol, Lipid Metabolites, and Lymphocytes: Worrisome Biomarkers for Intraductal Papillary Mucinous Neoplasms
Jafarnezhad‐Ansariha, F., Contran, N., Cristofori, C., Simonato, M., Davanzo, V., Moz, S., Galozzi, P., Fogar, P., Nordi, E., Padoan, A., et al. (2025) · Cancers · doi:10.3390/cancers17040643 · Cited by 4
Aryl Hydrocarbon Receptor Ligands Drive Pancreatic Cancer Initiation and Progression through Protumorigenic T-cell Polarization
Griffith, B. D., Kadiyala, P., McGue, J. J., Sun, L., Kumar, A., Espinoza, C. E., Donahue, K. L., Iyer, M. K., Speyer, C. B., Nelson, S., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0377 · Cited by 5
KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
Wei, Y., Liu, M., Yen, E.-Y., Yao, J., Xun, Z., Nguyen, P. T.-M., Wang, X., Yang, Z., Yousef, A. M. G., Pan, D. N., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2024 · Cited by 5
Self-citation
Molecular Aberrations in Periampullary Carcinoma
Tewari, M., Swain, J. R., Dixit, V. K., & Shukla, H. S. (2017) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-017-0645-2 · Cited by 5
Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer
Fu, J., Ling, J., Li, C.-F., Tsai, C.-L., Yin, W., Hou, J., Chen, P.-H., Cao, Y., Kang, Y., Sun, Y., et al. (2022) · bioRxiv · doi:10.1038/s41467-024-47242-3 · Cited by 3
Anti-Cancer Strategy Based on Changes in the Role of Autophagy Depending on the Survival Environment and Tumorigenesis Stages
Lee, M., & Kim, H. (2024) · Molecules · doi:10.3390/molecules29215134 · Cited by 4
Biotechnological advances in 3D modeling of cancer initiation. Examples from pancreatic cancer research and beyond
Handschin, C., Shalhoub, H., Mazet, A., Guyon, C., Dusserre, N., Boutet-Robinet, E. A., Oliveira, H., & Guillermet‐Guibert, J. (2025) · Biofabrication · doi:10.1088/1758-5090/adb51c · Cited by 5
Drivers of Pancreatic Cancer: Beyond the Big 4
Porcza, L. M., Ballesteros-Cillero, R., Lam, L. T., Maiello, C., & Leslie, N. R. (2025) · Cancers · doi:10.3390/cancers17142354 · Cited by 5
The Golgi: Keeping It Unapologetically Basic
Ward, N. P., & DeNicola, G. M. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0357 · Cited by 4
Die ambivalente Rolle des Tumormikromilieus bei soliden Tumoren
Gaida, M. M. (2020) · Der Pathologe · doi:10.1007/s00292-020-00837-1 · Cited by 4
Krüppel-Like Factor 4 Promotes Pancreatic Acinar-to-Ductal Metaplasia and Tumor Initiation
Xie, V. K., & Maitra, A. (2017) · Pancreas · doi:10.1097/mpa.0000000000000773 · Cited by 4
Tamoxifen calms down the distressed PDAC stroma
Pein, M., & Óskarsson, T. (2018) · EMBO Reports · doi:10.15252/embr.201847334 · Cited by 4
Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression
Ottaviani, S., Stebbing, J., Frampton, A. E., Zagorac, S., Krell, J., de Giorgio, A., Trabulo, S. M. D., Nguyen, V. T. M., Magnani, L., Feng, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11752-2 · Cited by 4
Palmitoyl transferase ZDHHC20 promotes pancreatic cancer metastasisPreprint
Tomić, G., Sheridan, C., Refermat, A. Y., Baggelaar, M. P., Sipthorp, J., Sudarshan, B., Ocasio, C. A., Suárez‐Bonnet, A., Priestnall, S. L., Herbert, E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.08.527637 · Cited by 4
Insight into the role of DNA methylation in prognosis and treatment response prediction of gastrointestinal cancers
Reyila, A., Gao, X., Yu, J. Q., & Nie, Y. (2025) · Epigenomics · doi:10.1080/17501911.2025.2476380 · Cited by 3
Prehabilitation as a Biologically Active Intervention Is Associated with the Remodeling of the Pancreatic Tumor-Immune Microenvironment
Stubbins, R., Li, B., Vasquez, M., Gorman, B. K., Zambelas, J. M., Allenson, K., Dhala, A. F., Dong, W., Zhao, H., & Wong, S. T. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020943 · Cited by 3
Selection of potential targets for stratifying congenital pulmonary airway malformation patients with molecular imaging: is MUC1 the one?
van Horik, C., Zuidweg, M. J. P., Munck, A. B., Kempen, M. B., Brosens, E., Vahrmeijer, A. L., von der Thüsen, J. H., Wijnen, R. M. H., Rottier, R. J., Tummers, W. S. F. J., et al. (2023) · European Respiratory Review · doi:10.1183/16000617.0217-2023 · Cited by 3
Effects of CCN6 overexpression on the cell motility and activation of p38/bone morphogenetic protein signaling pathways in pancreatic cancer cells
Nam, M.-W., Lee, H. K., Kim, C., Choi, Y., Ahn, D., Go, R., & Choi, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114780 · Cited by 3
Synthesis of 4‐Deoxy‐4‐Fluoro‐ d‐ Sedoheptulose: A Promising New Sugar to Apply the Principle of Metabolic Trapping
Scheibelberger, L., Stanković, T., Pühringer, M., Kählig, H., Balber, T., Patronas, E., Rampler, E., Mitterhauser, M., Haschemi, A., & Pallitsch, K. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202302277 · Cited by 3
Contrasting Historical Trends in Equatorial Indian Ocean Zonal Sea Surface Temperature Gradient in CMIP6 Models
Mohan, S., & Gopika, S. (2025) · International Journal of Climatology · doi:10.1002/joc.8832 · Cited by 3
Systemic Inflammatory Response in Pancreatic Ductal Adenocarcinoma
Silovs, A., Štrumfa, I., Riekstins, R., Simtniece, Z., Vanags, A., & Gardovskis, J. (2018) · InTech eBooks · doi:10.5772/intechopen.78954 · Cited by 3
Enhancement of gemcitabine cytotoxicity in pancreatic adenocarcinoma through controlled release of nitric oxide
Araujo‐Gutierrez, R., Eps, J. L. V., Kirui, D. K., Bryan, N. S., Kang, Y., Fleming, J. B., & Fernandez-Moure, J. S. (2019) · Biomedical Microdevices · doi:10.1007/s10544-019-0375-z · Cited by 3
Metabolism in Pancreatic Cancer
Poursaitidis, I., & Lamb, R. F. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_68 · Cited by 3
The Emergence of TRP Channels Interactome as a Potential Therapeutic Target in Pancreatic Ductal Adenocarcinoma
Wei, Y., Khalaf, A. T., Rui, C., Kadir, S. Y. A., Zainol, J., & Oglah, Z. (2023) · Biomedicines · doi:10.3390/biomedicines11041164 · Cited by 3
Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancerPreprint
Costa, D. B. V., Francescone, R., Franco‐Barraza, J., Luong, T., Graves, M., de Aquino, A. M., Steele, N. G., Gardiner, J. C., dos Santos, S. A. A., Ogier, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.15.594354 · Cited by 3
Wilms Tumor 1–Expressing Stromal Cells Promote Pancreatic Cancer Progression
Bischoff, A. C., Brown, K. L., Lasse-Opsahl, E., Watkoske, H. R., Espinoza, C. E., Okoye, J., Olivei, A., Green, L. M., Rai, R., The, S., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1014
Construction of an efferocytosis-related long non-coding ribonucleic acid scoring system to predict clinical outcome and immunotherapy response in pancreatic adenocarcinoma
Zhou, C., Gan, X., Sun, S., Wang, L., Zhang, Y., & Zhang, J. (2023) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2023.101540 · Cited by 2
Pyroptosis-related gene signature: A predictor for overall survival, immunotherapy response, and chemosensitivity in patients with pancreatic adenocarcinoma
Zhou, J., Jian, F., Li, B., Sun, J., & Wang, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23004 · Cited by 2
Pancreatic Diseases: Genetics and Modeling Using Human Pluripotent Stem Cells
Lee, Y., & Lee, K. (2024) · International Journal of Stem Cells · doi:10.15283/ijsc24036 · Cited by 2

Authors: Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Dana-Farber Cancer Institute (US)
ORCID: Ying, Haoqiang
Dey, Prasenjit
Yao, Wantong
Kimmelman, Alec C.
Draetta, Giulio F.
Maitra, Anirban
DePinho, Ronald A.
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 2016-02-15
Volume: 30
Issue: 4
Pages: 355-385
ISSN: 0890-9369 (ISSN-L)
1549-5477
DOI: 10.1101/gad.275776.115
OpenAlex: W4295846302
Cited by: 527
References: 392
Citations by year: 2026: 20 · 2025: 33 · 2024: 44 · 2023: 68 · 2022: 56 · 2021: 75 · 2020: 57 · 2019: 48 · 2018: 51 · 2017: 59 · 2016: 16
Type: posted content
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
Locations: Genes & Development (publishedVersion, cc-by-nc)
HighWire Press Open Archive (submittedVersion)
Funders: Sheikh Ahmed Center for Pancreatic Cancer Research
Pancreatic Cancer Moon Shot at the University of Texas MD Anderson Cancer Center
University of Texas Star Award (W81XWH-14-1-0429)
Department of Defense (U01DK108328, U01CA196403)
Odyssey Fellowship (Anne Eastland Spears Fellowship in GI Cancer Research)
University of Texas MD Anderson Cancer Center (RSG-13-298-01-TBG)
American Cancer Society (R01GM095567, R01CA157490, R01CA188048)
National Institutes of Health (14-90-25-DRAE, P01CA117969)
American Association for Cancer Research (W81XWH-11-1-0418)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords: pancreatic ductal adenocarcinoma, cancer genomics, molecular classification, cancer metabolism, DNA repair, tumor microenvironment, cancer immunotherapy, drug discovery, obesity, metabolic syndrome, preclinical models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genetics and biology of pancreatic ductal adenocarcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks